Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuronetics (STIM) Change in Receivables (2017 - 2025)

Neuronetics (STIM) has disclosed Change in Receivables for 9 consecutive years, with -$3.9 million as the latest value for Q3 2025.

  • On a quarterly basis, Change in Receivables fell 713.17% to -$3.9 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$1.5 million, a 131.51% decrease, with the full-year FY2024 number at $3.7 million, down 57.8% from a year prior.
  • Change in Receivables was -$3.9 million for Q3 2025 at Neuronetics, down from -$148000.0 in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $3.5 million in Q2 2022 to a low of -$3.9 million in Q3 2025.
  • A 5-year average of $1.1 million and a median of $898000.0 in 2023 define the central range for Change in Receivables.
  • Peak YoY movement for Change in Receivables: soared 369.8% in 2022, then plummeted 713.17% in 2025.
  • Neuronetics' Change in Receivables stood at $720000.0 in 2021, then surged by 187.92% to $2.1 million in 2022, then tumbled by 56.68% to $898000.0 in 2023, then plummeted by 111.92% to -$107000.0 in 2024, then plummeted by 3510.28% to -$3.9 million in 2025.
  • Per Business Quant, the three most recent readings for STIM's Change in Receivables are -$3.9 million (Q3 2025), -$148000.0 (Q2 2025), and $2.6 million (Q1 2025).